Organogenesis (NASDAQ:ORGO) Stock Price Down 6.2% – Here’s What Happened

Organogenesis Holdings Inc. (NASDAQ:ORGO) fell 6.2% during trading on Tuesday . The company traded as low as $4.99 and last traded at $5.08. 988,595 shares changed hands during trading, a decline of 6% from the average session volume of 1,055,866 shares. The stock had previously closed at $5.41.

Organogenesis Stock Performance

The stock has a market cap of $633.66 million, a P/E ratio of -84.00 and a beta of 1.77. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.74. The company has a fifty day moving average of $3.47 and a 200 day moving average of $3.28.

Insider Activity

In related news, CEO Gary S. Gillheeney sold 18,416 shares of the firm’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $3.65, for a total transaction of $67,218.40. Following the completion of the transaction, the chief executive officer now owns 3,400,778 shares of the company’s stock, valued at $12,412,839.70. This trade represents a 0.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In the last ninety days, insiders have sold 278,116 shares of company stock worth $991,190. 36.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Organogenesis

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Soleus Capital Management L.P. raised its holdings in shares of Organogenesis by 5.4% in the 4th quarter. Soleus Capital Management L.P. now owns 12,484,876 shares of the company’s stock worth $39,952,000 after purchasing an additional 645,000 shares in the last quarter. Assenagon Asset Management S.A. grew its position in Organogenesis by 54.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 2,950,849 shares of the company’s stock worth $9,443,000 after buying an additional 1,035,120 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Organogenesis by 18.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,789,265 shares of the company’s stock valued at $8,925,000 after buying an additional 442,772 shares in the last quarter. State Street Corp lifted its position in shares of Organogenesis by 0.6% during the 3rd quarter. State Street Corp now owns 1,459,767 shares of the company’s stock valued at $4,175,000 after acquiring an additional 9,090 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in shares of Organogenesis by 31.3% during the 4th quarter. Renaissance Technologies LLC now owns 1,073,500 shares of the company’s stock worth $3,435,000 after acquiring an additional 255,600 shares in the last quarter. 49.57% of the stock is owned by institutional investors and hedge funds.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.